


Stereochemistry abstracts

Dong Xiao,* Cheng Wang, Anandan Palani, Gregory Reichard,
Robert Aslanian, Neng-Yang Shih and Alexei Buevich

Tetrahedron: Asymmetry 17 (2006) 2596



Ee = 100%

$[\alpha]_D^{24} = +23.2$ (*c* 1.553, MeOH)

Source of chirality: asymmetric synthesis


Absolute configuration: 2(*S*),1'(*R*)

C₂₂H₂₃F₆NO

2(*S*)-[1(*R*)-(3,5-Bis-trifluoromethyl-phenyl)-ethoxymethyl]-2-phenyl-piperidine

Dong Xiao,* Cheng Wang, Anandan Palani, Gregory Reichard,
Robert Aslanian, Neng-Yang Shih and Alexei Buevich

Tetrahedron: Asymmetry 17 (2006) 2596



Ee = 100%

$[\alpha]_D^{24} = +84.7$ (*c* 1.00, EtOAc)

Source of chirality: asymmetric synthesis


Absolute configuration: (*R*)

C₁₈H₁₄F₆O₂

2-[1(*R*)-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-1-phenyl-ethanone

Dong Xiao,* Cheng Wang, Anandan Palani, Gregory Reichard,
Robert Aslanian, Neng-Yang Shih and Alexei Buevich

Tetrahedron: Asymmetry 17 (2006) 2596



Ee = 100%

$[\alpha]_D^{24} = +50.6$ (*c* 2.00, EtOAc)

Source of chirality: asymmetric synthesis


Absolute configuration: 2(*S*),1'(*R*)

C₂₂H₂₃F₆NO₂S

2-Methyl-propane-2-S(*S*)-sulfinic acid{2-[1-(*R*)-(3,5-bistrifluoromethyl-phenyl)-ethoxy]-1-phenyl-ethylidene}-amide

Dong Xiao,* Cheng Wang, Anandan Palani, Gregory Reichard,
Robert Aslanian, Neng-Yang Shih and Alexei Buevich

Tetrahedron: Asymmetry 17 (2006) 2596



Ee = 100%


$[\alpha]_D^{24} = -4.9$ (*c* 2.00, EtOAc)

Source of chirality: asymmetric synthesis

Absolute configuration: 2(*S*),1'(*S*),1''(*R*)

C₂₂H₁₉F₆NO₂S

2-Methyl-propane-2-S(*S*)-sulfinic acid{1-(*S*)-[1-(*R*)-(3,5-bistrifluoromethyl-phenyl)-ethoxymethyl]-1-phenyl-but-3-enyl}-amide



Ee = 100%


$[\alpha]_D^{24} = +9.2$ (*c* 1.00, EtOAc)

Source of chirality: asymmetric synthesis

Absolute configuration: 1(*S*),1'(*R*)

C₂₂H₂₃F₆NO₂

N-[1-(*S*)-[1-(*R*)-(3,5-Bis-trifluoromethyl-phenyl)-ethoxymethyl]-1-phenyl-but-3-enyl]-acrylamide



Ee = 100%


$[\alpha]_D^{24} = -7.5$ (*c* 1.00, EtOAc)

Source of chirality: asymmetric synthesis

Absolute configuration: 6(*S*),1'(*R*)

C₂₂H₁₉F₆NO₂

6(*S*)-[1-(*R*)-(3,5-Bis-trifluoromethyl-phenyl)-ethoxymethyl]-6-phenyl-5,6-dihydro-1*H*-pyridin-2-one



Ee = 100%


$[\alpha]_D^{24} = -103.8$ (*c* 1.00, EtOAc)

Source of chirality: asymmetric synthesis

Absolute configuration: 3(*R*),5(*S*),8a(*R*),1'(*R*)

C₂₅H₂₄F₆N₂O₂

5-[1-(*R*)-(3,5-Bis-trifluoromethyl-phenyl)-ethoxymethyl]-3-(*R*)-9-(*R*)phenyl-8a-(*R*)-hexahydro-oxazolo[3,2-a]pyridine-5-(*S*)-carbonitrile



Ee = 100%


$[\alpha]_D^{24} = -58.1$ (*c* 1.00, EtOAc)

Source of chirality: asymmetric synthesis

Absolute configuration: 3(*R*),5(*S*),8a(*R*),1'(*R*)

C₃₀H₂₉F₆NO₂

5-[1-(*R*)-(3,5-Bis-trifluoromethyl-phenyl)-ethoxymethyl]-3-(*R*),5-(*S*)-diphenyl-8a-(*R*)-hexahydro-oxazolo[3,2-a]pyridine




C₁₁H₁₃OP

(+)-(S)-1-Phenyl-3-methyl-3-phospholene 1-oxide

Ee = 99.0%

[α]_D²⁵ = +36.6 (c 1, CHCl₃)




C₄₂H₄₃O₅P

(+)-(S)-1-Phenyl-3-methyl-3-phospholene 1-oxide-(4*S*,5*S*)-(+)-4,5-bis(diphenylhydroxymethyl)-2,2-dimethyldioxolane complex

Ee = 99%

[α]_D²⁰ = +56.0 (c 1, CHCl₃)




C₁₅H₁₅NO₅S

Ethyl 2-(1,3-dioxoisooindolin-2-ylthio)-2-methyl-3-oxobutanoate

Ee = 41% [HPLC: *Daicel Chiralcel ODH* column,
hexane/iPrOH: 98.5/1.5, 0.5 mL/min; ret. times,
88.5 (minor), 100.9 (major) min]

[α]_D = -21.5 (c 10 mg/mL, CH₂Cl₂)

Source of chirality: asymmetric catalysis




C₂₀H₁₇NO₅S

Benzyl 2-(1,3-dioxoisooindolin-2-ylthio)-2-methyl-3-oxobutanoate

Ee = 42% [HPLC: *Chiraldak AS* column,
hexane/iPrOH: 96/4, 0.5 mL/min; ret. times,
69.3 (major), 75.8 (minor) min]

[α]_D = -23.1 (c 10 mg/mL, CH₂Cl₂)

Source of chirality: asymmetric catalysis




Ethyl 2-(1,3-dioxoisindolin-2-ylthio)-2-methyl-3-oxo-3-phenylpropanoate

Ee = 35% [HPLC: *Daicel Chiralcel ODH* column, hexane/ i PrOH: 98/2, 0.5 mL/min; ret. times, 66.7 (minor), 99.5 (major) min]

$[\alpha]_D = +19.5$ (c 5.75 mg/mL, CH_2Cl_2)

Source of chirality: asymmetric catalysis




Ethyl 1-(1,3-dioxoisindolin-2-ylthio)-2-oxocyclohexanecarboxylate

Ee = 60% [HPLC: *Daicel Chiralcel ODH* column, hexane/ i PrOH: 90/10, 0.5 mL/min; ret. times, 34.6 (minor), 46.1 (major) min]


$[\alpha]_D = -11.5$ (c 5.2 mg/mL, CH_2Cl_2)

Source of chirality: asymmetric catalysis

$[\alpha]_D^{25} = -63.7$ (c 0.5, $CHCl_3$)

3-O-Benzyl-5,6,8-trideoxy-1,2-O-isopropylidene- α -D-xylo-oct-5E-enofuranos-7-ulose


$[\alpha]_D^{25} = -37.2$ (c 0.8, $CHCl_3$)

3-O-Benzyl-5,6,8-trideoxy-1,2-O-isopropylidene- α -D-xylo-oct-5Z-enofuranos-7-ulose

Debendra K. Mohapatra,* Siddhartha Ray Chaudhuri,
Gokarneswar Sahoo and Mukund K. Gurjar*

Tetrahedron: Asymmetry 17 (2006) 2609

$$[\alpha]_D^{25} = +7.2 \text{ (c 1.0, CHCl}_3)$$




3-*O*-Benzyl-5,6-*C*-methylene-5,6,8-trideoxy-1,2-*O*-isopropylidene-*L*-glycero- β -*L*-iodo-octos-7-ulofuranose

Debendra K. Mohapatra,* Siddhartha Ray Chaudhuri,
Gokarneswar Sahoo and Mukund K. Gurjar*

Tetrahedron: Asymmetry 17 (2006) 2609

$$[\alpha]_D^{25} = +49.4 \text{ (c 1.0, CHCl}_3)$$




5,6-*C*-Methylene-5,6,8-trideoxy-1,2-*O*-isopropylidene-*L*-glycero- β -*L*-iodo-octos-7-ulofuranose

Debendra K. Mohapatra,* Siddhartha Ray Chaudhuri,
Gokarneswar Sahoo and Mukund K. Gurjar*

Tetrahedron: Asymmetry 17 (2006) 2609

$$[\alpha]_D^{25} = +46.7 \text{ (c 1.0, CHCl}_3)$$




3,5-*C*-Dimethyl-3,5,6,7,8-pentadeoxy-1,2-*O*-isopropylidene- β -L-talo-octofuranose

Debendra K. Mohapatra,* Siddhartha Ray Chaudhuri,
Gokarneswar Sahoo and Mukund K. Gurjar*

Tetrahedron: Asymmetry 17 (2006) 2609

$$[\alpha]_D^{25} = +25.6 \text{ (c 1.3, CHCl}_3)$$





(4*R*,5*S*,6*S*)-2,2,5-Trimethyl-4-((*S*)-pentan-2-yl)-6-vinyl-1,3-dioxane

Debendra K. Mohapatra,* Siddhartha Ray Chaudhuri,
Gokarneswar Sahoo and Mukund K. Gurjar*

Tetrahedron: Asymmetry 17 (2006) 2609

$$[\alpha]_D^{25} = +3.9 \text{ (c } 1.0, \text{ CHCl}_3\text{)}$$





(3*S*,4*S*,5*R*,6*S*)-5-(*tert*-Butyl-dimethyl-silanyloxy)-3-methoxy-4,6-dimethyl-non-1-ene

Debendra K. Mohapatra,* Siddhartha Ray Chaudhuri,
Gokarneswar Sahoo and Mukund K. Gurjar*

Tetrahedron: Asymmetry 17 (2006) 2609

$$[\alpha]_D^{25} = -23.9 \text{ (c } 0.8, \text{ CHCl}_3\text{)}$$




(3*S*,4*S*,5*R*,6*S*)-5-(*tert*-Butyl-dimethyl-silanyloxy)-3-methoxy-4,6-dimethyl-nonan-1-ol

Debendra K. Mohapatra,* Siddhartha Ray Chaudhuri,
Gokarneswar Sahoo and Mukund K. Gurjar*

Tetrahedron: Asymmetry 17 (2006) 2609

$$[\alpha]_D^{25} = -8.0 \text{ (c } 0.7, \text{ CHCl}_3\text{)}$$



(7*S*,8*S*,9*R*,10*S*)-9-(*tert*-Butyl-dimethyl-silanyloxy)-7-methoxy-8,10-dimethyl-trideca-2,4-dienoic acid methyl ester

Ashraf A. El-Shehawy


Tetrahedron: Asymmetry 17 (2006) 2617

Ee = 84%


$$[\alpha]_D^{25} = -57.4 \text{ (c } 1.03, \text{ CH}_2\text{Cl}_2\text{)}$$

Source of chirality: asymmetric synthesis

Absolute configuration: *S*




(*S*)-4-(1-Phenylpropyl)amino-3-mercaptop-6-methyl-4*H*-1,2,4-triazin-5-one

 $C_{14}H_{18}N_4OS$ (S)-4-[1-(2'-Methylphenyl)propyl]amino-3-mercaptop-6-methyl-4*H*-1,2,4-triazin-5-one

Ee = 79%

 $[\alpha]_D^{25} = -96.8$ (*c* 0.98, CHCl₃)


Source of chirality: asymmetric synthesis

Absolute configuration: *S* $C_{14}H_{18}N_4OS$ (S)-4-[1-(4'-Methylphenyl)propyl]amino-3-mercaptop-6-methyl-4*H*-1,2,4-triazin-5-one

Ee = 87%

 $[\alpha]_D^{25} = -78.1$ (*c* 1.28, CH₂Cl₂)


Source of chirality: asymmetric synthesis

Absolute configuration: *S* $C_{14}H_{18}N_4O_2S$ (S)-4-[1-(2'-Methoxyphenyl)propyl]amino-3-mercaptop-6-methyl-4*H*-1,2,4-triazin-5-one

Ee = 82%

 $[\alpha]_D^{25} = -94.5$ (*c* 0.77, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: *S* $C_{14}H_{18}N_4O_2S$ (S)-4-[1-(4'-Methoxyphenyl)propyl]amino-3-mercaptop-6-methyl-4*H*-1,2,4-triazin-5-one

Ee = 88% (92% after crystallization)

 $[\alpha]_D^{25} = -34.6$ (*c* 2.39, CH₂Cl₂)

Source of chirality: asymmetric synthesis

Absolute configuration: *S*




(*S*)-4-[1-(2',4',6'-Tri-methylphenyl)propyl]amino-3-mercaptop-6-methyl-4*H*-1,2,4-triazin-5-one

Ee = 72%

$[\alpha]_D^{25} = -46.6$ (*c* 0.98, CH₂Cl₂)

Source of chirality: asymmetric synthesis

Absolute configuration: *S*




(*S*)-Methyl-2-(2-formyl-1*H*-pyrrol-1-yl)propanoate

Ee >98%

$[\alpha]_D^{25} = -87.5$ (*c* 0.2, CHCl₃)

Source of chirality: L-alanine





(*S*)-Methyl-2-(2-formyl-1*H*-pyrrol-1-yl)-3-methylbutanoate

Ee >98%

$[\alpha]_D^{25} = +1.5$ (*c* 1.1, CHCl₃)

Source of chirality: L-valine




(*R*)-Methyl-2-(2-formyl-1*H*-pyrrol-1-yl)-2-phenyl acetate

Ee >98%


$[\alpha]_D^{25} = -104.4$ (*c* 0.2, CHCl₃)

Source of chirality: D-phenylglycine




$C_{15}H_{15}NO_3$
(*S*)-Methyl-2-(2-formyl-1*H*-pyrrol-1-yl)-3-phenylpropanoate

Ee >98%
 $[\alpha]_D^{25} = +8.8$ (*c* 0.2, CHCl₃)
 Source of chirality: L-phenylalanine




$C_{17}H_{18}N_2O_2$
(2*R*,3*S*,6*S*,10*aR*)-3,6-Dimethyl-2-phenyl-2,3-dihydro-10*bH*-[1,3]oxazolo[3,2-*a*]pyrrolo[2,1-*c*]pyrazin-5[6*H*]-one

$[\alpha]_D^{25} = -58.1$ (*c* 0.1, CHCl₃)





$C_{17}H_{18}N_2O_2$
(2*R*,3*S*,6*R*,10*aR*)-3,6-Dimethyl-2-phenyl-2,3-dihydro-10*bH*-[1,3]oxazolo[3,2-*a*]pyrrolo[2,1-*c*]pyrazin-5[6*H*]-one

$[\alpha]_D^{25} = -7.2$ (*c* 0.2, CHCl₃)





$C_{19}H_{22}N_2O_2$
(2*R*,3*S*,6*S*,10*aR*)-3-Methyl-6-isopropyl-2-phenyl-2,3-dihydro-10*bH*-[1,3]oxazolo[3,2-*a*]pyrrolo[2,1-*c*]pyrazin-5[6*H*]-one



$[\alpha]_D^{25} = -57.4$ (*c* 0.4, CHCl₃)

(2*R*,3*S*,6*R*,10*aR*)-3-Methyl-6-isopropyl-2-phenyl-2,3-dihydro-10*bH*-[1,3]oxazolo[3,2-*a*]pyrrolo[2,1-*c*]pyrazin-5[6*H*]-one



$[\alpha]_D^{25} = -28.2 \text{ (} c \text{ } 0.1, \text{ CHCl}_3 \text{)}$

(2*R*,3*S*,6*S*,10*aR*)-2,6-Diphenyl-3-methyl-2,3-dihydro-10*bH*-[1,3]oxazolo[3,2-*a*]pyrrolo[2,1-*c*]pyrazin-5[6*H*]-one


$[\alpha]_D^{25} = -75.4 \text{ (} c \text{ } 0.1, \text{ CHCl}_3 \text{)}$

(2*R*,3*S*,6*R*,10*aR*)-2,6-Diphenyl-3-methyl-2,3-dihydro-10*bH*-[1,3]oxazolo[3,2-*a*]pyrrolo[2,1-*c*]pyrazin-5[6*H*]-one


$[\alpha]_D^{25} = -63.0 \text{ (} c \text{ } 0.1, \text{ CHCl}_3 \text{)}$

(2*R*,3*S*,6*S*,10*aR*)-6-Benzyl-3-methyl-2-phenyl-2,3-dihydro-10*bH*-[1,3]oxazolo[3,2-*a*]pyrrolo[2,1-*c*]pyrazin-5[6*H*]-one


$[\alpha]_D^{25} = -23.0 \text{ (} c \text{ } 0.4, \text{ CHCl}_3 \text{)}$



$[\alpha]_D^{25} = -8.3$ (*c* 0.8, CHCl₃)



(2*R*,3*S*,6*R*,10*aR*)-6-Benzyl-3-methyl-2-phenyl-2,3-dihydro-10*bH*-[1,3]oxazolo[3,2-*a*]pyrrolo[2,1-*c*]pyrazin-5[6*H*]-one




Ee = 98%


$[\alpha]_D^{20} = +19.2$ (*c* 0.6, CHCl₃)

Source of chirality: (*R,R*)-1,2-diphenyl ethanediol

Absolute configuration: (2*R*,3*R*,1'*R*)



(2*R*,3*R*,1'*R*)-(+)-8-(1,5-Dimethyl-1-vinyl-4-hexenyl)-2,3-diphenyl-1,4-dioxaspiro[4.5]decan-8-ol




Ee = 98%


$[\alpha]_D^{20} = +36.4$ (*c* 1.0, CHCl₃)

Source of chirality: (*R,R*)-1,2-diphenyl ethanediol

Absolute configuration: (2*R*,3*R*,1'*R*)



(2*R*,3*R*,1'*R*)-(+)-8-(1,5-Dimethyl-1-vinyl-4-hexenyl)-2,3-diphenyl-1,4-dioxaspiro[4.5]dec-7-ene




Dr = >99% [NMR]


$[\alpha]_D^{20} = -73.65$ (*c* 0.72, Et₂O)

Source of chirality: Schöllkopf's reagent

Absolute configuration: (1'*R*,2*S*,5*R*)-(E)



(1'*R*,2*S*,5*R*)-(E)-3-Furan-2-yl-1-(5-isopropyl-3,6-dimethoxy-2,5-dihydro-pyrazin-2-yl)-prop-2-en-1-ol




$D_r = >99\% \text{ [NMR]}$


$[\alpha]_D^{20} = +58.2 (c \ 0.74, \text{Et}_2\text{O})$

Source of chirality: Schöllkopf's reagent

Absolute configuration: (1'S,2S,5R)-(E)



(1'S,2S,5R)-(E)-3-Furan-2-yl-1-(5-isopropyl-3,6-dimethoxy-2,5-dihydro-pyrazin-2-yl)-prop-2-en-1-ol



$D_r = >99\% \text{ [NMR]}$


$[\alpha]_D^{20} = +68.9 (c \ 0.83, \text{Et}_2\text{O})$

Source of chirality: Schöllkopf's reagent

Absolute configuration: (1'S,2R,5S)-(E)



(1'S,2R,5S)-(E)-3-Furan-2-yl-1-(5-isopropyl-3,6-dimethoxy-2,5-dihydro-pyrazin-2-yl)-prop-2-en-1-ol



$D_r = >99\% \text{ [NMR]}$


$[\alpha]_D^{20} = -49.9 (c \ 0.57, \text{Et}_2\text{O})$

Source of chirality: Schöllkopf's reagent

Absolute configuration: (1'R,2R,5S)-(E)



(1'R,2R,5S)-(E)-3-Furan-2-yl-1-(5-isopropyl-3,6-dimethoxy-2,5-dihydro-pyrazin-2-yl)-prop-2-en-1-ol



$D_r = >99\% \text{ [NMR]}$


$[\alpha]_D^{20} = -99.1 (c \ 0.89, \text{Et}_2\text{O})$

Source of chirality: Schöllkopf's reagent

Absolute configuration: (1'R,2S,5R)-(E)



(1'R,2S,5R)-(E)-1-(5-Isopropyl-3,6-dimethoxy-2,5-dihydro-pyrazin-2-yl)-3-thiazol-2-yl-prop-2-en-1-ol




Dr =>99% [NMR]


$[\alpha]_D^{20} = +82.9$ (*c* 0.57, Et₂O)

Source of chirality: Schöllkopf's reagent

Absolute configuration: (1'*S*,2*S*,5*R*)-(E)



(1'*S*,2*S*,5*R*)-(E)-1-(5-Isopropyl-3,6-dimethoxy-2,5-dihydro-pyrazin-2-yl)-3-thiazol-2-yl-prop-2-en-1-ol




Dr =>99% [NMR]


$[\alpha]_D^{20} = -28.4$ (*c* 1.2, Et₂O)

Source of chirality: Schöllkopf's reagent

Absolute configuration: (1'*R*,2*S*,5*R*)-(E)



(1'*R*,2*S*,5*R*)-(E)-1-(5-Isopropyl-3,6-dimethoxy-2,5-dihydro-pyrazin-2-yl)-3-thiophen-2-yl-prop-2-en-1-ol



Dr =>99% [NMR]


$[\alpha]_D^{20} = -82.4$ (*c* 0.66, Et₂O)

Source of chirality: Schöllkopf's reagent

Absolute configuration: (1'*R*,2*S*,5*R*)-(E)



(1'*R*,2*S*,5*R*)-(E)-1-(5-Isopropyl-3,6-dimethoxy-2,5-dihydro-pyrazin-2-yl)-3-(5-p-tolyl-isoxazol-3-yl)-prop-2-en-1-ol



Dr =>99% [NMR]


$[\alpha]_D^{20} = +63.5$ (*c* 0.20, Et₂O)

Source of chirality: Schöllkopf's reagent

Absolute configuration: (1'*S*,2*S*,5*R*)-(E)



(1'*S*,2*S*,5*R*)-(E)-1-(5-Isopropyl-3,6-dimethoxy-2,5-dihydro-pyrazin-2-yl)-3-(5-p-tolyl-isoxazol-3-yl)-prop-2-en-1-ol




$D_r = >99\% \text{ [NMR]}$


$[\alpha]_D^{20} = +27.0 (c \ 0.45, \text{CH}_3\text{COCH}_3)$

Source of chirality: asymmetric synthesis

Absolute configuration: (2S,3R)-(E)



(2S,3R)-(E)-2-Amino-5-furan-2-yl-3-hydroxy-pent-4-enoic acid methyl ester



$D_r = >99\% \text{ [NMR]}$


$[\alpha]_D^{20} = +14.5 (c \ 0.54, \text{CH}_3\text{COCH}_3)$

Source of chirality: asymmetric synthesis

Absolute configuration: (2S,3R)-(E)



(2S,3R)-(E)-2-Amino-3-hydroxy-5-thiazol-2-yl-pent-4-enoic acid methyl ester



$D_r = >99\% \text{ [NMR]}$


$[\alpha]_D^{20} = +14.0 (c \ 0.5, \text{CH}_3\text{COCH}_3)$

Source of chirality: asymmetric synthesis


Absolute configuration: (2S,3S)-(E)



(2S,3S)-(E)-2-Amino-3-hydroxy-5-thiazol-2-yl-pent-4-enoic acid methyl ester



$[\alpha]_D^{20.5} = -159.5 (c \ 1.10, \text{CHCl}_3)$




(S,E)-2-((2-(2,2,2-Trifluoro-1-hydroxyethyl)phenylimino)methyl)phenol

Yasser Samir Sokeirik, Masaaki Omote, Kazuyuki Sato,
Itsumaro Kumadaki and Akira Ando*

Tetrahedron: Asymmetry 17 (2006) 2654


$$[\alpha]_D^{20.5} = +32.7 \text{ (c } 1.40, \text{ CH}_3\text{OH})$$



$C_8H_8F_3NO$
(S)-1-(2-Aminophenyl)-2,2,2-trifluoroethanol

Noor-ul H. Khan,* Santosh Agrawal, Rukhsana I. Kureshy,
Sayed H. R. Abdi, Vishal J. Mayani and Raksh V. Jasra


Tetrahedron: Asymmetry 17 (2006) 2659



Poly[(R,R)-N,N'-bis-{3-(1,1-methyl)-5-methylene salicylidine}-cyclohexene-1,2-diamine vanadium(V)] ethylsulphate

Noor-ul H. Khan,* Santosh Agrawal, Rukhsana I. Kureshy,
Sayed H. R. Abdi, Vishal J. Mayani and Raksh V. Jasra

Tetrahedron: Asymmetry 17 (2006) 2659



Poly[(R,R)-N,N'-bis-{3-(1,1-dimethylethyl)-5-methylene salicylidine}-cyclohexene-1,2-diamine vanadium(V)] ethylsulphate

Noor-ul H. Khan,* Santosh Agrawal, Rukhsana I. Kureshy,
Sayed H. R. Abdi, Vishal J. Mayani and Raksh V. Jasra


Tetrahedron: Asymmetry 17 (2006) 2659

$$Ee = 94\%$$


$$[\alpha]_D^{27} = -31.5 \text{ (c } 1, \text{ CH}_2\text{Cl}_2)$$

Source of chirality: (1R,2R)-diaminocyclohexane

Absolute configuration: S



$C_{10}H_9NO_2$
(S)-2-O-Acetyl-2-phenyl acetonitrile



(S)-2-O-Acetyl-2-(2-methoxyphenyl) acetonitrile

Ee = 89%

[α]_D²⁷ = -25.6 (c 1, CH₂Cl₂)

Source of chirality: (1*R*,2*R*)-diaminocyclohexane

Absolute configuration: *S*



(S)-2-O-Acetyl-2-(4-fluorophenyl) acetonitrile

Ee = 80%

[α]_D²⁷ = -20.2 (c 1, CH₂Cl₂)

Source of chirality: (1*R*,2*R*)-diaminocyclohexane

Absolute configuration: *S*




(S)-2-O-Acetyl-2-(4-methoxyphenyl) acetonitrile

Ee = 86%

[α]_D²⁷ = -24.4 (c 1, CH₂Cl₂)

Source of chirality: (1*R*,2*R*)-diaminocyclohexane

Absolute configuration: *S*





(S)-2-O-Acetyl-2-(2-methylphenyl) acetonitrile

Ee = 96%

[α]_D²⁷ = -26.2 (c 1, CH₂Cl₂)

Source of chirality: (1*R*,2*R*)-diaminocyclohexane

Absolute configuration: *S*




(*S*)-2-*O*-Acetyl-2-(3-methoxyphenyl) acetonitrile

Ee = 82%

[α]_D²⁷ = -23.1 (*c* 1, CH₂Cl₂)

Source of chirality: (1*R*,2*R*)-diaminocyclohexane

Absolute configuration: *S*




(*S*)-2-*O*-Acetyl-2-(4-chlorophenyl) acetonitrile

Ee = 77%

[α]_D²⁷ = -10.2 (*c* 1, CH₂Cl₂)

Source of chirality: (1*R*,2*R*)-diaminocyclohexane

Absolute configuration: *S*




(*S*)-2-*O*-Acetyl-2-(4-bromophenyl) acetonitrile

Ee = 79%

[α]_D²⁷ = -11.6 (*c* 1, CH₂Cl₂)

Source of chirality: (1*R*,2*R*)-diaminocyclohexane

Absolute configuration: *S*




(*S*)-2-Hydroxy-*N*-(4-methoxy-benzyl)-3-phenyl-propionamide

[α]_D²⁵ = -71.1 (*c* 1.0, chloroform)

Chirality source: stereocontrolled synthesis from commercially available enantiopure compound

Absolute configuration: (*S*)


 $C_{18}H_{21}NO_5S$

Methanesulfonic acid (S)-1-(4-methoxy-benzylcarba-moyl)-2-phenyl-ethyl ester

 $[\alpha]_D^{25} = -66.0$ (*c* 1.00, chloroform)

Chirality source: stereocontrolled synthesis from commercially available enantiopure compound

Absolute configuration: (S)


 $C_{17}H_{18}N_4O_2$

(R)-2-Azido-N-(4-methoxy-benzyl)-3-phenyl-propionamide

 $[\alpha]_D^{25} = -21.8$ (*c* 1.00, chloroform)

Chirality source: stereocontrolled synthesis from commercially available enantiopure compound

Absolute configuration: (S)


 $C_9H_{11}NO_2$

(R)-Phenylalanine

 $[\alpha]_D^{25} = -7.3$ (*c* 1.00, acetic acid)

Chirality source: stereocontrolled synthesis from commercially available enantiopure compound

Absolute configuration: (S)



 $C_{24}H_{25}NO_5S$

Toluene-4-sulfonic acid (S)-1-(4-methoxy-benzylcarbamoyl)-2-phenyl-ethyl ester



 $[\alpha]_D^{25} = -50.4$ (*c* 1.0, chloroform)

Chirality source: stereocontrolled synthesis from commercially available enantiopure compound


Absolute configuration: (S)

Acetic acid (*S*)-1-(4-methoxy-benzylcarbamoyl)-2-phenyl-ethyl ester $[\alpha]_D^{25} = -10.9$ (*c* 1.0, chloroform)



Chirality source: stereocontrolled synthesis from commercially available enantiopure compound

Absolute configuration: (*S*)(4*S*)-4-[(1-Hydroxyl-1-methyl)-ethyl]-2-[(2-hydroxyl-3,5-di-tert-butyl)-phenyl]-4,5-dihydro-1,3-oxazoline $[\alpha]_D^{27} = +3.3$ (*c* 1.0, $CHCl_3$)


Source of chirality: L-serine

(4*S*)-4-Hydroxymethyl-5,5-dimethyl-2-[(2-hydroxyl-3,5-di-tert-butyl)-phenyl]-4,5-dihydro-1,3-oxazoline $[\alpha]_D^{27} = -30.8$ (*c* 1.0, $CHCl_3$)


Source of chirality: L-serine

(4*S*)-4-[(1-Ethyl-1-hydroxyl-propyl)-2-[(2-hydroxyl-3,5-di-tert-butyl)-phenyl]-4,5-dihydro-1,3-oxazoline $[\alpha]_D^{27} = -1.2$ (*c* 1.0, $CHCl_3$)


Source of chirality: L-serine

 $C_{22}H_{35}NO_3$ (4*S*)-4-Hydroxymethyl-5,5-diethyl-2-[(2-hydroxyl-3,5-di-*tert*-butyl)-phenyl]-4,5-dihydro-1,3-oxazoline $[\alpha]_D^{27} = -24.5$ (*c* 1.0, CHCl₃)

Source of chirality: L-serine

 $C_{30}H_{35}NO_3$ (4*S*)-4-(Hydroxyl-diphenyl)-methyl-2-[(2-hydroxyl-3,5-di-*tert*-butyl)-phenyl]-4,5-dihydro-1,3-oxazoline $[\alpha]_D^{27} = -41.2$ (*c* 1.0, CHCl₃)

Source of chirality: L-serine


 $C_{30}H_{35}NO_3$ (4*S*)-4-Hydroxymethyl-5,5-diphenyl-2-[(2-hydroxyl-3,5-di-*tert*-butyl)-phenyl]-4,5-dihydro-1,3-oxazoline $[\alpha]_D^{27} = -232.5$ (*c* 1.0, CHCl₃)

Source of chirality: L-serine

 $[\alpha]_D^{25} = +115$ (*c* 0.34, acetone)

de ~100% (NMR)



Source of chirality: asymmetric synthesis

 $C_6H_{10}O_3$ (2*R*,3*S*)-2,3-Dihydroxy-3-methyl-cyclopentanone

$[\alpha]_D^{22} = +243$ (*c* 0.80, MeOH)

de ~100% (NMR)


Source of chirality: asymmetric synthesis



(2*S*,5*R*)-2,5-Dihydroxy-2-methyl-cyclopentanone

$[\alpha]_D^{25} = -38$ (*c* 2.47, CHCl₃)


Source of chirality: asymmetric synthesis



(2*S*)-2-Hydroxy-5,5-dimethoxy-3-methyl-cyclopentanone

$[\alpha]_D^{24} = +125$ (*c* 1.75, CHCl₃)

Source of chirality: asymmetric synthesis




(3a*S*,6a*S*)-3a-Hydroxy-2,2,6a-trimethyl-tetrahydro-cyclopenta[1,3]dioxol-4-one


$[\alpha]_D^{25} = -96$ (*c* 3.55, CHCl₃)

de ~100% (NMR)

Source of chirality: asymmetric synthesis



(3a*R*,4*R*,6a*S*)-2,2,6a-Trimethyl-tetrahydro-cyclopenta[1,3]dioxole-3a,4-diol




$C_8H_{17}NO_5$
4,4-Diethoxy-1-nitrobutan-2-ol

Ee = 92% by HPLC on Chiracel OD column

$[\alpha]_D^{23} = -10.4$ (*c* 1.22, CHCl₃)

Source of chirality: *Candida antartica* lipase catalysed desymmetrisation by acylation

Absolute configuration: *R*




$C_7H_{13}NO_7$
1-(Hydroxymethyl)-6-nitrocyclohexane-1,2,3,5-tetraol

$[\alpha]_D^{23} = -33.3$ (*c* 4.25, CH₃OH)

Source of chirality: RAMA aldolase catalysed aldolisation

Absolute configuration: 1*S*,2*S*,3*R*,5*S*,6*R*




$C_7H_{13}NO_7$
1-(Hydroxymethyl)-6-nitrocyclohexane-1,2,3,5-tetraol

$[\alpha]_D^{23} = +27$ (*c* 2.67, CH₃OH)

Source of chirality: RAMA aldolase catalysed aldolisation

Absolute configuration: 1*R*,2*S*,3*R*,5*R*,6*S*




$C_7H_{15}NO_5$
6-Amino-1-(hydroxymethyl)cyclohexane-1,2,3,5-tetraol

$[\alpha]_D^{23} = -7.9$ (*c* 1.1, H₂O)

Source of chirality: RAMA aldolase catalysed aldolisation

Absolute configuration: 1*S*,2*S*,3*R*,5*S*,6*R*




6-Amino-1-(hydroxymethyl)cyclohexane-1,2,3,5-tetraol

[α]_D²³ = +6.6 (c 1.2, H₂O)

Source of chirality: RAMA aldolase catalysed aldolisation

Absolute configuration: 1R,2S,3R,5R,6S




Ethyl hydroxy(phenyl)methane(P-phenyl)phosphinate

Ee = 87%

[α]_D²³ = +2.8 (c 1.67, CH₃Cl, 23 °C)

Source of chirality: kinetic resolution

Absolute configuration: (R_P,S)




Methyl 2-azido-2-deoxy-3,4:5,6-di-O-isopropylidene-D-mannonate **13**

Ee = 100%

[α]_D²² = +21.5 (c 0.69, CHCl₃)

Source of chirality: D-glucono-1,5-lactone as starting material



Methyl 4-azido-5,6:7,8-di-O-isopropylidene-2,3,4-trideoxy-D-manno-oct-2-enoate **14**


Ee = 100%

[α]_D²² = +35.5 (c 0.71, CHCl₃)

Source of chirality: D-glucono-1,5-lactone as starting material

Jeroen Van Ameijde, Graeme Horne, Mark R. Wormald,
Raymond A. Dwek, Robert J. Nash, Paul Wyn Jones,
Emma L. Evinson and George W. J. Fleet*

Tetrahedron: Asymmetry 17 (2006) 2702



4-Deoxy-2,3-di-O-tert-butyldimethylsilyl-5,6:7,8-di-O-isopropylidene-D-erythro-L-alto-octono-1,4-lactam **17**


Ee = 100%

$[\alpha]_D^{22} = +1.8$ (*c* 1.59, CHCl₃)

Source of chirality: D-glucono-1,5-lactone as starting material

Jeroen Van Ameijde, Graeme Horne, Mark R. Wormald,
Raymond A. Dwek, Robert J. Nash, Paul Wyn Jones,
Emma L. Evinson and George W. J. Fleet*

Tetrahedron: Asymmetry 17 (2006) 2702



4-Deoxy-2,3-di-O-tert-butyldimethylsilyl-5,6-O-isopropylidene-D-erythro-L-alto-octono-1,4-lactam **18**


Ee = 100%

$[\alpha]_D^{23} = +2.9$ (*c* 0.41, CHCl₃)

Source of chirality: D-glucono-1,5-lactone as starting material

Jeroen Van Ameijde, Graeme Horne, Mark R. Wormald,
Raymond A. Dwek, Robert J. Nash, Paul Wyn Jones,
Emma L. Evinson and George W. J. Fleet*

Tetrahedron: Asymmetry 17 (2006) 2702



4-Deoxy-5,6-O-isopropylidene-7-O-methanesulfonyl-2,3,8-tri-O-tert-butyldimethylsilyl-D-erythro-L-alto-octono-1,4-lactam **19**


Ee = 100%

$[\alpha]_D^{23} = +28.9$ (*c* 0.37, CHCl₃)

Source of chirality: D-glucono-1,5-lactone as starting material

Jeroen Van Ameijde, Graeme Horne, Mark R. Wormald,
Raymond A. Dwek, Robert J. Nash, Paul Wyn Jones,
Emma L. Evinson and George W. J. Fleet*

Tetrahedron: Asymmetry 17 (2006) 2702



1,4-Dideoxy-1,4-imino-5,6-O-isopropylidene-7-O-methanesulfonyl-2,3,8-tri-O-tert-butyldimethylsilyl-D-erythro-L-alto-octitol **20**


Ee = 100%

$[\alpha]_D^{24} = -67.1$ (*c* 0.38, CHCl₃)

Source of chirality: D-glucono-1,5-lactone as starting material

Jeroen Van Ameijde, Graeme Horne, Mark R. Wormald,
Raymond A. Dwek, Robert J. Nash, Paul Wyn Jones,
Emma L. Evinson and George W. J. Fleet*

Tetrahedron: Asymmetry 17 (2006) 2702



3-*epi*-Casuarine **1**



Ee = 100%

$[\alpha]_D^{22} = +5.8$ (*c* 0.69, H₂O)

Source of chirality: D-glucono-1,5-lactone as starting material

Jeroen Van Ameijde, Graeme Horne, Mark R. Wormald,
Raymond A. Dwek, Robert J. Nash, Paul Wyn Jones,
Emma L. Evinson and George W. J. Fleet*

Tetrahedron: Asymmetry 17 (2006) 2702



4-Deoxy-5,6-O-isopropylidene-2,3,8-tri-O-tert-butyldimethylsilyl-D-*erythro*-L-*altro*-octono-1,4-lactam **22**


Ee = 100%

$[\alpha]_D^{23} = +13.5$ (*c* 0.65, CHCl₃)

Source of chirality: D-glucono-1,5-lactone as starting material

Jeroen Van Ameijde, Graeme Horne, Mark R. Wormald,
Raymond A. Dwek, Robert J. Nash, Paul Wyn Jones,
Emma L. Evinson and George W. J. Fleet*

Tetrahedron: Asymmetry 17 (2006) 2702



4-Deoxy-5,6-O-isopropylidene-2,3,8-tri-O-tert-butyldimethylsilyl-L-*threo*-L-*altro*-octono-1,4-lactam **24**


Ee = 100%

$[\alpha]_D^{23} = +11.1$ (*c* 0.55, CHCl₃)

Source of chirality: D-glucono-1,5-lactone as starting material

Jeroen Van Ameijde, Graeme Horne, Mark R. Wormald,
Raymond A. Dwek, Robert J. Nash, Paul Wyn Jones,
Emma L. Evinson and George W. J. Fleet*

Tetrahedron: Asymmetry 17 (2006) 2702



4-Deoxy-5,6-O-isopropylidene-7-O-methanesulfonyl-2,3,8-tri-O-tert-butyldimethylsilyl-L-*threo*-L-*altro*-octono-1,4-lactam **25**


Ee = 100%

$[\alpha]_D^{22} = +6.0$ (*c* 0.57, CHCl₃)

Source of chirality: D-glucono-1,5-lactone as starting material

Jeroen Van Ameijde, Graeme Horne, Mark R. Wormald,
Raymond A. Dwek, Robert J. Nash, Paul Wyn Jones,
Emma L. Evinson and George W. J. Fleet*

Tetrahedron: Asymmetry 17 (2006) 2702



1,4-Dideoxy-1,4-imino-5,6-O-isopropylidene-7-O-methanesulfonyl-2,3,8-tri-O-tert-butyldimethylsilyl-L-threo-L-alto-octitol **26**


Ee = 100%

$[\alpha]_D^{23} = -8.5$ (*c* 1.32, CHCl₃)

Source of chirality: D-glucono-1,5-lactone as starting material

Jeroen Van Ameijde, Graeme Horne, Mark R. Wormald,
Raymond A. Dwek, Robert J. Nash, Paul Wyn Jones,
Emma L. Evinson and George W. J. Fleet*

Tetrahedron: Asymmetry 17 (2006) 2702



Casuarine **2**


Ee = 100%

$[\alpha]_D^{23} = +16.8$ (*c* 0.33, H₂O)

Source of chirality: D-glucono-1,5-lactone as starting material

Michelangelo Gruttaduria,* Paolo Lo Meo, Serena Riela,
Francesca D'Anna and Renato Noto

Tetrahedron: Asymmetry 17 (2006) 2713



(*R*)-1-Chloro-3-(phenylseleno)-propan-2-yl acetate



Ee = 95%

$[\alpha]_D^{23} = -8.8$ (*c* 0.30, CHCl₃)

Absolute configuration: *R*

Michelangelo Gruttaduria,* Paolo Lo Meo, Serena Riela,
Francesca D'Anna and Renato Noto

Tetrahedron: Asymmetry 17 (2006) 2713




(*R,R*)-2,3-Dihydro-1-(phenylseleno)-1*H*-inden-2-yl acetate

Ee = >99%

$[\alpha]_D^{27} = +25.6$ (*c* 1.19, CHCl₃)


Absolute configuration: *R,R*



C₁₈H₁₈O₂Se

(*R,R*)-1,2,3,4-Tetrahydro-2-(phenylseleno)naphthalen-1-yl acetate


Ee = 96%
[α]_D²⁶ = -51.2 (*c* 0.26, CHCl₃)
Absolute configuration: *R,R*



C₁₂H₁₄O₂Se

(*R*)-1-(Phenylseleno)-but-3-en-2-yl acetate


Ee = 80%
[α]_D²⁶ = -5.4 (*c* 0.99, CHCl₃)
Absolute configuration: *R*



C₁₃H₁₆O₂Se

(*R*)-1-(Phenylseleno)-pent-4-en-2-yl acetate

Ee = 94%
[α]_D²⁶ = -16.2 (*c* 0.87, CHCl₃)
Absolute configuration: *R*




C₉H₁₁ClOSe

(*S*)-1-Chloro-3-(phenylseleno)-propan-2-ol


Ee = 84%
[α]_D²³ = +19.25 (*c* 0.32, CHCl₃)
Absolute configuration: *S*

Ee = 44%
 $[\alpha]_D^{26} = -8.6$ (*c* 0.90, CHCl₃)
Absolute configuration: *R*




C₁₄H₁₄OSe
(*R*)-1-Phenyl-2-(phenylseleno)ethanol

Ee = 46%
 $[\alpha]_D^{26} = +13.2$ (*c* 1.38, CHCl₃)
Absolute configuration: *S*




C₁₆H₁₆O₂Se
(*S*)-1-Phenyl-2-(phenylseleno)ethyl acetate

Ee = >99%
 $[\alpha]_D^{28} = -2.2$ (*c* 1.02, CHCl₃)
Absolute configuration: *R,R*




C₁₃H₁₆O₂Se
(*R,R*)-2-(Phenylseleno)-cyclopentyl acetate

Ee = 58%
 $[\alpha]_D^{25} = +4.1$ (*c* 0.73, CHCl₃)
Absolute configuration: *S*




C₁₂H₁₂OSSe
(*S*)-2-(Phenylseleno)-1-thiophen-2-yl-ethanol




C₁₅H₁₄OSe
(S,S)-2,3-Dihydro-2-(phenylseleno)-1*H*-inden-1-ol

Ee = >99%
 $[\alpha]_D^{26} = +3.7$ (*c* 0.83, CHCl₃)
Absolute configuration: *S,S*



C₁₁H₁₄OSe
(*S*)-1-(Phenylseleno)-pent-4-en-2-ol

Ee = >99%
 $[\alpha]_D^{26} = +30.65$ (*c* 0.65, CHCl₃)
Absolute configuration: *S*



C₁₂H₁₆OSe
(*S*)-1-(Phenylseleno)-hex-5-en-2-ol

Ee = 85%
 $[\alpha]_D^{24} = +36.3$ (*c* 0.83, CHCl₃)
Absolute configuration: *S*